Dermatologic Therapy最新文献

{"title":"Preliminary Clinical Study of Monopolar Versus Bipolar Fractional Microneedling Radiofrequency for Facial Rejuvenation","authors":"Yidan Xu, Hao Wang, Yanjun Zhou, Huimiao Tang, Xiang Wen","doi":"10.1155/dth/3331924","DOIUrl":"https://doi.org/10.1155/dth/3331924","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Fractional microneedling radiofrequency (FMR) is a promising minimally invasive treatment for skin rejuvenation. This pilot study aims to investigate and compare the efficacy and safety of monopolar versus bipolar FMR in the treatment for facial rejuvenation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective, split-face pilot study, 20 female patients aged 35–55 years were enrolled. Participants underwent a single session with one side of the face receiving monopolar FMR and the other side receiving bipolar FMR randomly. Post-treatment assessments for biometric and aging characteristics using Corneometer, Tewameter, Cutometer, Antera 3D, and VISIA, as well as blinded investigators’ evaluation and patients’ assessed improvement, were conducted at 40 ± 7 days after the procedure. Adverse effects were monitored 3–6 days after treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nineteen participants completed this trial. 40 ± 7 days post-treatment, a significant increase in overall skin elasticity was noted on both sides of the face. No significant changes were observed in skin hydration, transepidermal water loss (TEWL), melanin, and erythema indices, and no differences were noted between the monopolar and bipolar groups. Antera 3D showed a significant reduction in average pore count, density, size, and volume in the bipolar group and in average pore density and volume in the monopolar group. Both modes of FMR significantly improved small textures (monopolar: 7.11 ± 1.45 to 6.58 ± 1.17, bipolar: 7.12 ± 1.23 to 6.55 ± 1.22; <i>p</i> < 0.05, <i>p</i> < 0.05). Significant improvements in small wrinkles and texture were also detected. Bipolar FMR showed superior results in pore count, size, and volume compared to monopolar FMR but was associated with significantly more pain. Patients reported overall satisfaction post-treatment, with no significant difference between the two sides. After the procedure, mild to moderate erythema and edema were noted, without any severe side effects. Scab formation occurred exclusively on the bipolar-treated side.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Monopolar and bipolar FMR are effective and safe for addressing aging with minimal adverse effects. Bipolar FMR offers better outcomes in terms of facial pores but may cause higher discomfort and longer recovery periods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Chinese Clinical Trial Registry: ChiC","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3331924","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145317248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Dupilumab Efficacy and Safety in Pediatric Patients: A Real-World Experience Over 2 Years","authors":"Daniele Omar Traini,&nbsp;Cristina Guerriero,&nbsp;Giulia Coscarella,&nbsp;Lorenzo Maria Pinto,&nbsp;Niccolò Gori,&nbsp;Gerardo Palmisano,&nbsp;Ketty Peris","doi":"10.1155/dth/4857510","DOIUrl":"https://doi.org/10.1155/dth/4857510","url":null,"abstract":"<p>In this exploratory retrospective, single-center observational study, we evaluated the long-term effectiveness and safety of dupilumab in 42 pediatric patients with moderate-to-severe atopic dermatitis (AD), including individuals with rare genetic syndromes. We also explored the feasibility of seasonal dosing modulation. During the summer months (June–August), patients underwent an extended dupilumab dosing interval (from every 2 weeks to every 3 weeks or from every 4 weeks to every 5 weeks), taking advantage of the typical seasonal improvement in AD symptoms. At 24 months, mean EASI scores were significantly reduced from 21.2 at baseline to 1.6 (<i>p</i> &lt; 0.0001), and substantial improvements were observed in both P-NRS and sleep quality, with 95% of patients achieving at least a 50% improvement by week 16. Although the summer dosing extension maintained disease control in all patients, 21 (50%) required a return to standard dosing in autumn to sustain efficacy. Dupilumab was well-tolerated, with conjunctivitis being the sole adverse event, reported in 9.5% of patients and resolving without the need to discontinue therapy. These results underscore dupilumab’s sustained efficacy and safety in a complex pediatric population and support the potential of seasonal dose modulation as a tailored treatment strategy.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4857510","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145317080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Differences in Epidemiology, Mechanisms, and Management of Atopic Dermatitis","authors":"Martina Maurelli,&nbsp;Paolo Gisondi,&nbsp;Micol Del Giglio,&nbsp;Giampiero Girolomoni","doi":"10.1155/dth/6670747","DOIUrl":"https://doi.org/10.1155/dth/6670747","url":null,"abstract":"<p>Sex differences in disease are of increasing importance. They depend primarily on the hormonal status, which can influence immune responses and metabolic pathways, as well as response to treatments. Sex differences have been described for both innate and adaptive immune cells, and sex hormones are important regulators of Th2 immunity. Atopic dermatitis (AD) is a common inflammatory skin disorder with a chronic and relapsing course. AD prevalence rates have increased over recent decades, especially in urbanized and industrialized regions. Approximately 5%–20% of children and 5%–8% of adults suffer from AD. AD is more prevalent in adolescent females and females of child-bearing age, who also suffer from more severe and persistent AD symptoms compared to males. Menstrual periods and pregnancy frequently lead to a worsening of AD symptoms. Indeed, estrogens potentiate, while androgens reduce Th2 immune response and increase T regulatory cell activity. Sex hormones also affect the skin barrier function. Monoclonal antibodies against Th2 cytokines are more effective in females. Major concerns about treatment arise in pregnant females and those planning a pregnancy. Only cyclosporine and azathioprine (off-label) are suggested in pregnancy when the benefits exceed the potential side effects, but they are both contraindicated during breastfeeding. Methotrexate and systemic corticosteroids are contraindicated during pregnancy and lactation. Some reports have described safe and effective use of dupilumab during pregnancy, but evidence remains limited; therefore, it is not recommended during pregnancy because of the scarce data on safety. There is no data about tralokinumab and lebrikizumab use during pregnancy, so their use is preventively avoided. Abrocitinib, baricitinib, and upadacitinib are contraindicated during pregnancy and breastfeeding, and some teratogenic effects have been described in animal models.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6670747","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eczematous Eruption on Hands and Feet After Treatment With Biological Agents for Psoriasis","authors":"Fen Peng,&nbsp;Hio Fong Leong,&nbsp;Zhi-Lin Sun,&nbsp;Wen-Hui Wang","doi":"10.1155/dth/1668153","DOIUrl":"https://doi.org/10.1155/dth/1668153","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To summarize and analyze the clinical diagnosis and patient management of immune drift in psoriasis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Review the cases of psoriasis patients in the Peking University Third Hospital dermatology inpatient room from 2022 to 2023 and analyze three patients who developed eczema on hands and feet after treatment with biological agents. Review databases such as PubMed, Medline, and Embase databases to summarize the cases of immune drift induced by biological therapy for psoriasis reported in the literature.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 57 patients were included in the literature search combined with the 3 patients reported in this article for discussion. In previous studies, the biologics involved include the following: adalimumab (22 cases), infliximab (5 cases), etanercept (6 cases), ixekizumab (7 cases), secukinumab (10 cases), ustekinumab (15 cases), and guselkumab (3 cases). Among them, 8 patients experienced immune drift reactions to more than one biological agent. Among these patients, the proportion of male patients is 54%, and the proportion of female patients is 46%, with the age being (42.5 ± 24.5) years. The time from the initiation of biologic therapies to the onset of eczematous rash varies from 4 days to 22 months. The main manifestation included erythema, papules with exudation or scales, and the affected areas include the scalp, face, neck, trunk, and limbs. In previous studies, 47 patients reported laboratory indicators, of which 23 (48.9%) had elevated eosinophils and 9 (19.1%) had elevated IgE levels. A total of 10 patients reported biopsy results, all of which were consistent with eczema. Previous studies have reported 34 cases of treatment outcomes. Among them, 23 cases stopped using their original biologics and were changed to other types of biologics or small-molecule drugs, or treated with systemic glucocorticoids, cyclosporine, and methotrexate. In addition, 11 cases continued to use their previous biologics, of which 8 patients improved after topical glucocorticoids treatment and 3 cases did not receive any treatment and improved. Among the 3 patients reported in this article, 2 had elevated serum total IgE and 1 had elevated eosinophils. The three patients all stopped using previous biologics and improved after treatment with other types of biologics or systemic glucocorticoids and immunosuppressants.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Biologic therapy plays an important role in the treatment of psoriasis, but their","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1668153","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sorafenib-Related Dermatologic Toxicity: A Comprehensive Evaluation Based on Disproportionality Analysis and Clinical Characteristics","authors":"Yiling Ding,&nbsp;Zhen Wang,&nbsp;Yamin Shu,&nbsp;Ying Tang,&nbsp;Qilin Zhang","doi":"10.1155/dth/1667726","DOIUrl":"https://doi.org/10.1155/dth/1667726","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Recognized as the primary treatment for unresectable hepatocellular carcinoma (HCC) and as an approved therapeutic agent for renal cell carcinoma (RCC) and differentiated thyroid carcinoma (DTC), sorafenib is often limited in long-term clinical application due to dermatologic toxicity, which may necessitate dose modifications or even treatment discontinuation. The present study sought to comprehensively characterize these toxicities through mining of the Food and Drug Administration Adverse Event Reporting System (FAERS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using FAERS reports collected between the first quarter (Q1) of 2018 and Q1 of 2023, we applied disproportionality analysis, calculating reporting odds ratios (RORs) to compare sorafenib-related dermatologic toxicity with the overall database. Comparisons were made between serious and nonserious reports, followed by signal prioritization using a predefined scoring system. To evaluate the consistency of these findings, stratification analyses were undertaken. Moreover, univariate logistic regression was applied to investigate potential determinants of sorafenib-related dermatologic AEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Reports of dermatologic toxicity accounted for 32.36% of the overall sorafenib reports during the study period, and 72 adverse events (AEs) were defined as sorafenib-related dermatologic toxicity. Reports of sorafenib-associated dermatologic toxicity indicated a median patient age of 64 years (interquartile range [IQR] 56–72) and a median time-to-onset (TTO) of 11 days (IQR: 0.5–37.5), with serious outcomes accounting for 89.07% of cases. Besides, 1, 15, and 16 AEs were identified as signals with strong, moderate, and weak clinical priority, respectively, all displaying an early failure pattern. Sex and reporter types were significant influencing factors for sorafenib-associated dermatic AEs (male: OR = 0.667 [0.577–0.772], <i>p</i> &lt; 0.01; healthcare professional: OR = 0.760 [0.661–0.874], <i>p</i> &lt; 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study characterized the clinical features, TTO, severity profiles, clinical prioritization, and influencing factors of sorafenib-associated dermatologic toxicities. The findings offer supportive evidence to aid clinicians in managing AEs, thereby enhancing patient adherence and therapeutic outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1667726","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab as a Therapeutic Option in Autoimmune Bullous Diseases Following SARS-CoV-2 Infection and COVID-19 Vaccination: A Comprehensive Case Series Analysis","authors":"Francesca Svara,&nbsp;Vito Gomes,&nbsp;Chiara Battilotti,&nbsp;Nicolò Sini,&nbsp;Alvise Sernicola,&nbsp;Camilla Chello,&nbsp;Ester Del Duca,&nbsp;Annunziata Dattola,&nbsp;Steven Paul Nisticò,&nbsp;Giovanni Pellacani,&nbsp;Teresa Grieco","doi":"10.1155/dth/2257832","DOIUrl":"https://doi.org/10.1155/dth/2257832","url":null,"abstract":"<p>The global vaccination campaign against SARS-CoV-2, started in December 2021, is the primary defense against COVID-19. Since then, the scientific community has been actively investigating the potential increase in autoimmune and autoinflammatory conditions linked to both the infection and vaccination, particularly with recombinant-mRNA Comirnaty (BNT162b2) and Spikevax vaccines. Within this context, increasing reports of autoimmune bullous diseases (AIBD) have been published in the literature. We present the cases of 4 patients diagnosed with AIBD, two males and two females aged between 19 and 82 years that presented generalized bullous eruptions following COVID-19 disease and vaccination. All patients underwent the same diagnostic and therapeutic protocol in agreement with the current international guidelines. Dupilumab, an anti-IL 4/13 biologic drug approved for moderate to severe atopic dermatitis, was chosen as long-term corticosteroid-sparing immunomodulating therapy. Dupilumab was administered at 600 mg loading dose followed by 300 mg biweekly. Three patients achieved complete remission and stopped corticosteroids, maintaining disease long-term control. The fourth, with pemphigus vulgaris, was unresponsive and subsequently received rituximab. The aim of our study was to recognize the features of SARS-CoV-2 and COVID-19 vaccination–related AIBDs. Additionally, we evaluated the response and tolerability to dupilumab, as an alternative adjunctive treatment to traditional systemic immunosuppressants and suggested potential diagnostic and clinical markers of response to dupilumab therapy in AIBDs.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2257832","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 1064 and 532 nm Picosecond Fractional Lasers for Treating Enlarged Pores and Melanin Spots in Asians: A Randomized Split-Section Comparison Study","authors":"Kento Takaya,&nbsp;Kazuo Kishi","doi":"10.1155/dth/5584699","DOIUrl":"https://doi.org/10.1155/dth/5584699","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This split-face randomized study compared the efficacy and safety of 532 and 1064 nm picosecond (ps) fractional lasers for treating enlarged pores and melanin spots.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Participants with enlarged facial pores and melanin spots were enrolled and underwent five consecutive sessions of either the 1064 or 532 nm ps fractional laser, with 1-month intervals between treatments. Images were taken at each visit. Treatment efficacy was assessed by objective (number of pores and melanin spots) and subjective evaluations (patient self-assessment and a quartile improvement scale). Pain levels, sensation of irritation, and side effects were recorded at subsequent follow-ups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three Asian males and 22 Asian females were enrolled in this study. At the 2-month follow-up after the final treatment, both wavelengths showed a significant reduction in pore numbers on both sides. The respective quartile improvement scale scores showed no significant difference between the two groups. For melanin spot improvement, the mean improvement scale scores were 1.72 ± 0.46 for the 532 nm wavelength and 1.49 ± 0.22 for the 1064 nm wavelength, with the 532 nm wavelength demonstrating a statistically significant and moderately clinically meaningful improvement. Patient assessments showed in pore improvement between the two wavelengths; however, significant improvement in melanin spots was observed for the 532 nm wavelength. The 532 nm wavelength was significantly less painful and irritating.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The 532 and 1064 nm ps fractional lasers are effective at treating enlarged pores, and although they each demonstrate comparable efficacy, the 532 nm laser also provides simultaneous improvement in melanin spots and is better tolerated.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5584699","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Safety and Efficacy of Dupilumab in Pediatric Atopic Dermatitis Patients","authors":"Hilla Bauch-Eigner,&nbsp;Hiba Zaaroura,&nbsp;Marwan Dawood,&nbsp;Ziyad Khamaysi,&nbsp;Emily Avitan-Hersh,&nbsp;Orna Mirmovitch-Morvay","doi":"10.1155/dth/6997815","DOIUrl":"https://doi.org/10.1155/dth/6997815","url":null,"abstract":"<p>Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition affecting up to 20% of children globally. Recent therapeutic advances include the introduction of dupilumab, a fully human monoclonal antibody targeting the IL-4 receptor alpha chain, crucial in type 2 inflammation. While dupilumab’s efficacy in moderate to severe pediatric AD is established, long-term safety data remain sparse. This retrospective cohort study included 14 pediatrics patients with moderate to severe AD, treated with dupilumab for up to 72 months (39.6 ± 22.6 months, range: 13–72). Most patients (11/14, 78.57%) had a personal history of other atopic comorbidities and were hospitalized at least once (10/13, 76.92%) due to exacerbation of their disease. Six of the 14 patients (42.85%) achieved a complete response, while the remaining eight (57.14%) demonstrated a partial response, most within 2 months. All patients experienced significant reductions in both hospitalizations and local skin infections. Adverse events (AEs) were infrequent, experienced by 21.43% (3/14) of the patients. All AEs were mild, causing no treatment discontinuations. These findings align with existing literature, suggesting that dupilumab is a safe and effective long-term treatment option for pediatric AD, offering sustained disease control and improved quality of life.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6997815","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Alopecia Areata and High-Sensitivity Cardiac Troponin T as a Marker of Subclinical Myocardial Injury","authors":"Akam Ramezani,&nbsp;Robabeh Abedini,&nbsp;Ifa Etesami,&nbsp;Shahin Hamzelou,&nbsp;Amirali Barkhordarioon,&nbsp;Safoura Shakoei","doi":"10.1155/dth/6034179","DOIUrl":"https://doi.org/10.1155/dth/6034179","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Alopecia areata (AA) is a common autoimmune disorder characterized by nonscarring hair loss, affecting up to 2% of the population. While primarily a dermatological condition, recent studies have explored possible systemic associations, including cardiovascular involvement. Troponins have been a focal point in examining cardiovascular risks in various autoimmune diseases. This study aims to evaluate and compare High-sensitivity cardiac troponin T (hs-cTnT) levels in patients with AA against healthy controls to explore potential cardiovascular risk associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this cross-sectional study, 45 patients with AA and 45 age- and sex-matched healthy individuals were enrolled. Demographic characteristics of patients, medical history, and lifestyle factors were gathered through questionnaires. Patient blood samples were collected, and hs-cTnT levels were determined using high-sensitivity immunoassays to provide accurate measurements. Statistical analyses were conducted using the SPSS software. Statistical significance was set at <i>p</i> &lt; 0.05.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both study groups comprised of 26 male and 19 female participants. The mean age of the AA group was 37.33 ± 12.49, and the mean age of the control group was 36.22 ± 12.28. Of the patients with AA, 73.3% had patchy areata, 11.1% had totalis areata, and 15.6% had universalis areata. The mean hs-cTnT levels in the AA group were 4.29 ± 3.54 and 2.87 ± 2.05 for the control group (<i>p</i> value = 0.04). The disease duration exhibited a positive correlation with elevated concentrations of hs-cTnT (<i>p</i> value &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Elevated hs-cTnT levels in patients with AA strengthen the link between AA and cardiovascular diseases. Additional research is needed to clarify the relationship between AA and elevated cardiac markers. Studies with larger sample sizes, long-term follow-ups, and comprehensive cardiac assessments (including laboratory tests and imaging techniques) can provide more definitive evidence to determine the cause of the increased marker levels.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6034179","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Secukinumab and Ixekizumab on Clinical and Psychological Outcomes in Psoriasis Patients: A Multicenter Prospective Cohort Study","authors":"Min Dai,&nbsp;Yuxiong Jiang,&nbsp;Yu Wang,&nbsp;Dawei Huang,&nbsp;Yifan Hu,&nbsp;Shan Wang,&nbsp;Yuling Shi","doi":"10.1155/dth/7025415","DOIUrl":"https://doi.org/10.1155/dth/7025415","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriasis is a chronic inflammatory skin disorder that impacts both physical and psychological health. Secukinumab and ixekizumab, IL-17A inhibitors, are used for moderate-to-severe psoriasis, but their comparative efficacy remains underexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study evaluates the efficacy of secukinumab and ixekizumab in a Chinese cohort, focusing on both clinical and psychological outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective, multicenter, observational study included 176 patients treated with secukinumab and 106 patients treated with ixekizumab. Key clinical and psychological outcomes were measured at baseline and Week 12, including PASI, PGA, DLQI, PtGA, and HADS. HADS included achieving HADS-A or HADS-D score of 0 and changes in HADS scores from baseline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Secukinumab and ixekizumab achieved comparable efficacy at Week 12 in PASI 75, PASI 90, and PGA 0/1 responses (<i>p</i> &gt; 0.05). However, secukinumab significantly outperformed ixekizumab in psychological outcomes. A higher proportion of patients with secukinumab achieved HADS-A = 0 (49% vs. 28%) and HADS-D = 0 (31% vs. 19%) (<i>p</i> &lt; 0.05). The least squares (LS) mean changes from baseline in HADS-A or HADS-D scores were more pronounced in the secukinumab group. Subgroup analysis showed no significant differences in achieving HADS-A = 0 or HADS-D = 0 across clinical characteristics within the secukinumab group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Secukinumab and ixekizumab showed similar clinical efficacy in treating moderate-to-severe psoriasis, but secukinumab provided superior psychological benefits, particularly in reducing anxiety and depression symptoms. These findings highlight the potential of secukinumab to provide enhanced psychological outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7025415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}